A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: December 14, 2007
Last updated: May 13, 2013
Last verified: May 2013
The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin. The clinical effects of the drug in combination with insulin on the body will also be studied. The results will help determine doses of GSK189075 can be studied in the future in the type I diabetes mellitus population.

Condition Intervention Phase
Diabetes Mellitus, Type 1
Type 1 Diabetes Mellitus
Drug: GSK189075
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Single Ascending Dose Escalation, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 Administered to Subjects With Type 1 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • blood & urine samples: [ Time Frame: day 1 ]

Secondary Outcome Measures:
  • Adverse events, heart rate, blood pressure, ECG, clinical laboratory tests: [ Time Frame: screening, check-in, day 1,follow-up ]

Enrollment: 14
Study Start Date: March 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm a
Drug: GSK189075
investigational drug
Placebo Comparator: Arm b
Drug: placebo
placebo comparator
Other Name: GSK189075


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male/female, 18 to 55 years old
  • Diagnosis of type 1 diabetes mellitus for at least 6 months; and using a continuous insulin pump
  • Willing and able to follow all study-related instructions provided by the site staff.
  • Willing to provide signed informed consent.

Exclusion Criteria:

  • Pregnant or a nursing female.
  • Have a past or current disease such as heart, liver, kidney, blood, brain, or other disease.
  • Have HIV or hepatitis, or have alcohol or drugs in your system at the screening visit.
  • Have a history of alcohol abuse or have an eating disorder
  • Have been in another research study in the last month or have taken certain medications in the 1 week before study drug would be taken.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00575159

United States, California
GSK Investigational Site
San Diego, California, United States, 92161
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00575159     History of Changes
Other Study ID Numbers: KGI107465 
Study First Received: December 14, 2007
Last Updated: May 13, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Adult male and females,
type 1 Diabetes mellitus, pharmacokinetics,

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on May 26, 2016